Pancreatic Cancer Research

ResearcherTokyo Metropolitan Komagome HospitalActive in the last 2 years

Yuki Homma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6560-2895; OpenAlex author ID A5064428590. Sources: OpenAlex.

Their work

Papers
22 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
63
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 4 papers · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 5 papers · 2026: 1 paper

Papers 22

  1. High CDCP1 Expression Reflects Immune and Stromal Remodeling and Oncogenic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.14740/wjon2682↗
  2. Novel machine-learning model for predicting lymph node metastasis in resectable pancreatic ductal adenocarcinoma. First author DOI 10.1002/ags3.12836↗
  3. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Co-author DOI 10.1002/ags3.70001↗
  4. Clinical Relevance of High-Grade Pancreatic Intraepithelial Neoplasia at the Pancreatic Transection Margin in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-17400-y↗
  5. ASO Author Reflections: A New Proposal for Therapeutic Strategies in Patients with High-Grade Pancreatic Intraepithelial Neoplasia at the Pancreatic Transectio… Co-author DOI 10.1245/s10434-025-17508-1↗
  6. Prognostic Significance of Post-Neoadjuvant Chemotherapy Carbohydrate Antigen 19-9 Levels in Patients With Resectable Pancreatic Cancer Treated With S-1 and Ge… Co-author DOI 10.14740/wjon2563↗
  7. Outcomes of neoadjuvant gemcitabine plus S-1 and radiation therapy for borderline resectable pancreatic cancer. Co-author DOI 10.1002/jhbp.1245↗
  8. Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis. Co-author DOI 10.1002/jhbp.1127↗
  9. CRMP4 Up-regulates M2 Macrophages and Myeloid-derived Suppressor Cells to Promote Pancreatic Cancer in Mice. Co-author DOI 10.21873/anticanres.15537↗
  10. Reduction of gender-associated M2-like tumor-associated macrophages in the tumor microenvironment of patients with pancreatic cancer after neoadjuvant chemorad… Co-author DOI 10.1002/jhbp.883↗
  11. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse… Co-author DOI 10.1016/j.canlet.2020.07.034↗
  12. Role of the tumor microenvironment in pancreatic cancer. Co-author DOI 10.1002/ags3.12225↗
  13. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Fo… Co-author DOI 10.1007/s00268-019-05159-9↗
  14. Efficacy of prolonged elemental diet therapy after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: A pilot prospective randomized trial (UMIN0000… Co-author DOI 10.1016/j.clnesp.2019.07.017↗
  15. MiR-194-5p in Pancreatic Ductal Adenocarcinoma Peritoneal Washings is Associated with Peritoneal Recurrence and Overall Survival in Peritoneal Cytology-Negativ… Co-author DOI 10.1245/s10434-019-07793-y↗
  16. Tumor-Targeting Salmonella typhimurium A1-R Promotes Tumoricidal CD8+ T Cell Tumor Infiltration and Arrests Growth and Metastasis in a Syngeneic Pancreatic-Can… Co-author DOI 10.1002/jcb.26224↗
  17. [III. Resection Margins and R1 Resection in Pancreatic Cancer]. Co-author PMID 30382038↗
  18. Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility co… First author DOI 10.1002/jso.24681↗
  19. MZB1 in borderline resectable pancreatic cancer resected after neoadjuvant chemoradiotherapy. Co-author DOI 10.1016/j.jss.2017.07.003↗
  20. [Neoadjuvant Chemotherapy Using S-1 for Pancreatic Cancer - Mid-Term Results]. Co-author PMID 27760934↗
  21. Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer. Co-author DOI 10.1007/s12094-013-1079-0↗
  22. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1245/s10434-013-3390-y↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Itaru Endo · 20 shared papers, 2014–2026 · strength 2.76
  2. Kentaro Miyake · 12 shared papers, 2017–2026 · strength 2.01
  3. Yasuhiro Yabushita · 8 shared papers, 2018–2025 · strength 1.41
  4. Takashi Murakami · 8 shared papers, 2014–2021 · strength 0.66
  5. Yukihiko Hiroshima · 6 shared papers, 2017–2022 · strength 0.61
  6. Kei Kobayashi · 2 shared papers, 2025 · strength 0.49
  7. Jun Yamamoto · 2 shared papers, 2020–2026 · strength 0.38
  8. Robert M. Hoffman · 4 shared papers, 2017–2020 · strength 0.33
  9. Masanori Oshi · 1 shared paper, 2026 · strength 0.29
  10. Yuko Mataki · 2 shared papers, 2022–2025 · strength 0.28
  11. Hiroki Ohya · 1 shared paper, 2025 · strength 0.25
  12. Susumu Daibo · 1 shared paper, 2025 · strength 0.25
  13. Michael Bouvet · 3 shared papers, 2017–2020 · strength 0.22
  14. Hirokazu Kubo · 2 shared papers, 2019 · strength 0.19
  15. Yosuke Inoue · 1 shared paper, 2025 · strength 0.17
  16. So Yamaki · 1 shared paper, 2025 · strength 0.17
  17. Sohei Satoi · 1 shared paper, 2025 · strength 0.17
  18. Tetsuya Ikemoto · 1 shared paper, 2025 · strength 0.17
  19. Yasunari Kawabata · 1 shared paper, 2025 · strength 0.17
  20. Katsuhisa Hirano · 1 shared paper, 2025 · strength 0.17
  21. Joji Kitayama · 1 shared paper, 2025 · strength 0.17
  22. Masamichi Mizuma · 1 shared paper, 2025 · strength 0.17
  23. Toshimichi Asano · 1 shared paper, 2025 · strength 0.17
  24. Atsushi Oba · 1 shared paper, 2025 · strength 0.17
  25. Yasutoshi Kimura · 1 shared paper, 2025 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.